HC Wainwright Analysts Raise Earnings Estimates for Cardiff Oncology, Inc. (NASDAQ:CRDF)

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Equities research analysts at HC Wainwright upped their FY2024 earnings per share estimates for Cardiff Oncology in a report released on Monday, May 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.98) for the year, up from their prior estimate of ($0.99). HC Wainwright currently has a “Buy” rating and a $14.00 price target on the stock. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.97) per share.

Cardiff Oncology (NASDAQ:CRDF) last released its earnings results on Thursday, February 29th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.05. Cardiff Oncology had a negative net margin of 6,594.92% and a negative return on equity of 54.54%. The firm had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.08 million.

Separately, Piper Sandler raised their price objective on Cardiff Oncology from $5.00 to $7.00 and gave the company an “overweight” rating in a research note on Friday, March 1st.

Cardiff Oncology Stock Performance

Shares of CRDF stock opened at $3.20 on Thursday. Cardiff Oncology has a fifty-two week low of $0.94 and a fifty-two week high of $6.42. The stock’s fifty day moving average price is $4.63 and its two-hundred day moving average price is $2.55. The company has a market cap of $143.10 million, a PE ratio of -3.56 and a beta of 2.02.

Institutional Trading of Cardiff Oncology

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Callan Capital LLC raised its holdings in Cardiff Oncology by 129.2% in the 3rd quarter. Callan Capital LLC now owns 31,147 shares of the company’s stock valued at $43,000 after buying an additional 17,560 shares during the last quarter. PFG Investments LLC acquired a new position in shares of Cardiff Oncology during the first quarter worth $53,000. Finally, Assenagon Asset Management S.A. bought a new stake in shares of Cardiff Oncology in the first quarter worth $1,351,000. Institutional investors own 16.29% of the company’s stock.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.